Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Launches Second Stage of Manufacturing of Ibogaine for Clinical Research
The company has filed patent applications for two routes of chemical synthesis of ibogaine – offering potential advantages of improved isomeric purity, chiral purity, and easily isolated intermediate compounds Preliminary data indicates that the drug shows promise as a treatment for neuropathic pain and migraines, as well as the treatment of addiction The company is positioned to engage several markets, including digital therapeutics and research Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (“MINDCURE”), a diversified life sciences company at the forefront of the mental health industry, recently announced the launch of its second manufacturing stage of pharmaceutical-grade ibogaine to be…
